Pelthos Therapeutics (PTHS)
:PTHS
Total Valuation
Pelthos Therapeutics has a market cap or net worth of $76.84M. The enterprise value is $31.66M.
Market Cap$76.84M
Enterprise Value$31.66M
Share Statistics
Pelthos Therapeutics has 3,355,543 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,355,543
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pelthos Therapeutics’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -26.38%.
Return on Equity (ROE)-1.11
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-26.38%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee4.20M
Profits Per Employee-10.83M
Employee Count4
Asset Turnover0.13
Inventory Turnover0.27
Valuation Ratios
The current PE Ratio of Pelthos Therapeutics is ―. Pelthos Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio3.47
PB Ratio1.50
Price to Fair Value1.50
Price to FCF-2.57
Price to Operating Cash Flow-3.18
PEG Ratio-0.02
Income Statement
In the last 12 months, Pelthos Therapeutics had revenue of 16.80M and earned -43.32M in profits. Earnings per share was -23.04.
Revenue16.80M
Gross Profit10.52M
Operating Income-32.43M
Pretax Income-50.71M
Net Income-43.32M
EBITDA-30.07M
Earnings Per Share (EPS)-23.04
Cash Flow
In the last 12 months, operating cash flow was -22.59M and capital expenditures -99.00K, giving a free cash flow of -22.69M billion.
Operating Cash Flow-22.59M
Free Cash Flow-22.69M
Free Cash Flow per Share-6.76
Dividends & Yields
Pelthos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.92
52-Week Price Change64.75%
50-Day Moving Average22.96
200-Day Moving Average25.15
Relative Strength Index (RSI)50.91
Average Volume (3m)30.94K
Important Dates
Pelthos Therapeutics upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Pelthos Therapeutics as a current ratio of 2.03, with Debt / Equity ratio of 89.58%
Current Ratio2.03
Quick Ratio1.12
Debt to Market Cap0.55
Net Debt to EBITDA-0.56
Interest Coverage Ratio-10.77
Taxes
In the past 12 months, Pelthos Therapeutics has paid -7.39M in taxes.
Income Tax-7.39M
Effective Tax Rate0.15
Enterprise Valuation
Pelthos Therapeutics EV to EBITDA ratio is -2.50, with an EV/FCF ratio of -3.31.
EV to Sales4.47
EV to EBITDA-2.50
EV to Free Cash Flow-3.31
EV to Operating Cash Flow-3.32
Balance Sheet
Pelthos Therapeutics has $18.02M in cash and marketable securities with $34.83M in debt, giving a net cash position of -$16.80M billion.
Cash & Marketable Securities$18.02M
Total Debt$34.83M
Net Cash-$16.80M
Net Cash Per Share-$5.01
Tangible Book Value Per Share-$13.44
Margins
Gross margin is 62.65%, with operating margin of -193.09%, and net profit margin of -257.93%.
Gross Margin62.65%
Operating Margin-193.09%
Pretax Margin-301.91%
Net Profit Margin-257.93%
EBITDA Margin-179.05%
EBIT Margin-193.09%
Analyst Forecast
The average price target for Pelthos Therapeutics is $57.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$57.14
Price Target Upside149.52% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―